Get started
Author

Godfrey Musoro

Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa
2017 · James Hakim, Victor Musiime, et al. · New England Journal of Medicine · 209
PDF
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
2022 · Nicholas I Paton, Joseph Musaazi, et al. · The Lancet HIV · 138
PDF
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
2017 · Nicholas I Paton, Cissy Kityo, et al. · The Lancet HIV · 79
PDF
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial
2020 · Pauline D J Bollen, Cecilia L Moore, et al. · The Lancet HIV · 47
PDF
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
2017 · James G Hakim, Jennifer Thompson, et al. · The Lancet Infectious Diseases · 43
PDF
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
2022 · Hylke Waalewijn, Man K Chan, et al. · The Lancet HIV · 40
Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial
2018 · Frank A Post, Alexander J Szubert, et al. · Clinical Infectious Diseases · 40
PDF
Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial
2018 · Cissy Kityo, Alexander J. Szubert, et al. · PLoS Medicine · 38
PDF
High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy
2013 · Ravindra K. Gupta, Ruth L. Goodall, et al. · Clinical Infectious Diseases · 38
PDF
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
2022 · Pauline Amuge, Abbas Lugemwa, et al. · The Lancet HIV · 36
PDF
Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial
2018 · Abraham Siika, Leanne McCabe, et al. · Clinical Infectious Diseases · 33
PDF
Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial
2015 · For the EARNEST Trial Team, Alejandro Arenas-Pinto, et al. · Journal of NeuroVirology · 32
Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial
2018 · Jane Mallewa, Alexander J Szubert, et al. · The Lancet HIV · 31
PDF
Oral abstracts of the 21st International AIDS Conference 18-22 July 2016, Durban, South Africa
2016 · Ericsen, A, Lauck, M, et al. · Journal of the International AIDS Society · 27
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
2022 · Anna Turkova, Hylke Waalewijn, et al. · The Lancet HIV · 24
PDF
Second-Line Antiretroviral Therapy for Children Living with HIV in Africa
2025 · Victor Musiime, Mutsa Bwakura-Dangarembizi, et al. · New England Journal of Medicine · 20
Prevalence, incidence and predictors of peripheral neuropathy in African adults with HIV infection within the DART trial
2014 · Sylvia Kiwuwa-Muyingo, Bernard Kikaire, et al. · AIDS · 15
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
2023 · Anna Turkova, Ellen White, et al. · The Lancet Child & Adolescent Health · 14
PDF
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial
2018 · Jennifer A Thompson, Cissy Kityo, et al. · Clinical Infectious Diseases · 11
PDF
Oral step-down, optimal drug, and total duration of antibiotic treatment in African children hospitalised with severe community-acquired pneumonia (PediCAP): a factorial randomised controlled trial
2026 · Julia A Bielicki, Michelle Clements, et al. · The Lancet · 5
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial
2026 · Anna Turkova, Ellen White, et al. · The Lancet Child & Adolescent Health · 3
New Insights on Long-Term Hepatitis B Virus Responses in HIV–Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings
2020 · David Dunn, Huw Price, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 3
PDF
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min
2019 · Lisa L. Ross, A. Sarah Walker, et al. · PLoS ONE · 3
PDF
Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda
2014 · R. L. Goodall, D. T. Dunn, et al. · Journal of Antimicrobial Chemotherapy · 3
PDF
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa
2026 · Diana Anena, Elizabeth Chappell, et al. · Contemporary Clinical Trials · 2
Works count: 40
Citation count: 940
H-index: 16
I10-index: 19
Year
Topic
Type